<DOC>
	<DOCNO>NCT03039231</DOCNO>
	<brief_summary>This study test efficacy Freespira Breathing System adults post traumatic stress disorder ( PTSD ) .</brief_summary>
	<brief_title>Investigation Freespira Breathing System Treatment Post Traumatic Stress Disorder ( PTSD )</brief_title>
	<detailed_description>The Freespira Breathing System ( FBS ) develop Palo Alto Health Sciences , Inc , portable home device , employ breathe biofeedback adult panic disorder ( PD ) . The FBS receive FDA clearance treatment PD adult currently commercially available . This study prospective , single arm , un-blinded investigation Freespira Breathing System PTSD population .</detailed_description>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<criteria>Note : Office visit require . Patients must live locally San Francisco/Silicon Valley Bay Area participate . Patients primary diagnosis PTSD Additional DSMV disorder acceptable document . Subjects 18 year age Subjects Clinician 's Global Impression ( CGIS ) score ≥ 4 Subjects CAPS5 score ≥ 30 If psychotropic medication ( ) , stable dose course treatment This include benzodiazepine use prescribe need basis . • If psychotropic medication ( ) , patient agreement maintain current stable dose point study entry 2month posttreatment assessment . Subject pregnant . Current enrollment another device drug study . Enrollment another drug device study least 30 day past final followup visit . Currently undergo cognitive behavioral therapy , equivalent focus address PTSD include evidence base therapy focus PTSD , include cognitive processing therapy , EMDR , prolong exposure therapy , Virtual reality therapy , trial 2 month follow . Cognitive therapy must discontinue 1 month prior enrol study . Severe suicidality , judgment interviewer take CHART assessment account Psychotic disorder diagnosis , include schizophrenia schizoaffective disorder Presence uncontrolled bipolar disorder describe The subject experience manic episode past 6 month consider control reviewer Bipolar disorder consider primary diagnosis subject , interviewer 's opinion . No Alcohol , drug use disorder require medical treatment . If stable medical supervision treatment drug/alcohol use , OK Cardiovascular pulmonary disease , COPD . Score ≥ 10 COPD assessment EtCO2 ≥ 48 mmHg first treatment visit Epilepsy seizures Inability understand comply study procedure . The investigator feel reason subject eligible participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PTSD</keyword>
</DOC>